LeMaitre Vascular, Inc. (LMAT)

LeMaitre Vascular reported Q3 2025 EPS of $0.75, surpassing expectations by 31.58%, with revenue at $61.0 million, an 11% year-over-year increase. The company reported strong Q2 2025 financial results with sales reaching $64.2 million, up 15% year-over-year. The Board of Directors approved a quarterly dividend of $0.20 per share. The company's Board of Directors authorized the repurchase of up to $75.0 million of its common stock. Several insider sales were reported in August and December 2025. As of January 15, 2026, LeMaitre Vascular had a short interest of 1.23 million shares, representing 5.98% of the public float.

Specific information regarding the demand seasonality for LeMaitre Vascular's products and services was not explicitly detailed. The company's consistent revenue growth and expansion of its sales force suggest a generally stable and growing demand for its vascular intervention products globally, driven by new products, regulatory approvals, and demographic trends.

LeMaitre Vascular, Inc. (LMAT) is a medical device company in the Healthcare sector, specifically the Medical Instruments & Supplies industry. It develops, manufactures, and markets medical devices for vascular surgeons treating peripheral vascular disease (PVD), end-stage renal disease, and other cardiovascular conditions. The company offers biologic products like Artegraft and XenoSure, catheters for blood clot removal and perfusion, grafts including allografts and biosynthetic vascular grafts, surgical devices such as angioscopes and phlebectomy systems, and human cadaver tissue cryopreservation services.

LeMaitre Vascular, Inc. has a global presence, manufacturing in the U.S. and distributing worldwide. It sells directly to hospitals in 25 countries and uses distributors in over 70 countries across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Sales growth in Q3 2025 was strongest in EMEA at +18%, followed by the Americas at +10% and APAC at +4%.

LeMaitre Vascular is recognized for its strong product portfolio and innovative medical devices, focusing on specific niches within vascular surgery. The European launch of Artegraft has contributed to accelerated growth in grafts. No specific events negatively impacted LeMaitre Vascular's brand reputation in the past year were identified. The company's continued expansion of its direct sales force also reflects confidence in future growth and product traction.

LeMaitre Vascular, Inc. has a diverse ownership structure, with institutional investors holding approximately 92.1% of the shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Conestoga Capital Advisors, LLC. George W. LeMaitre, the Chairman and CEO, directly owned 7.63% of the company's shares. Insiders collectively owned about 9.97% of the shares.